Seres Therapeutics (MCRB) Total Liabilities: 2015-2025
Historic Total Liabilities for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $99.8 million.
- Seres Therapeutics' Total Liabilities fell 35.55% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 35.55%. This contributed to the annual value of $126.0 million for FY2024, which is 68.76% down from last year.
- Seres Therapeutics' Total Liabilities amounted to $99.8 million in Q3 2025, which was down 9.99% from $110.8 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Total Liabilities ranged from a high of $408.8 million in Q2 2024 and a low of $99.8 million during Q3 2025.
- Over the past 3 years, Seres Therapeutics' median Total Liabilities value was $318.1 million (recorded in 2023), while the average stood at $263.9 million.
- In the last 5 years, Seres Therapeutics' Total Liabilities soared by 56.71% in 2023 and then plummeted by 72.88% in 2025.
- Over the past 5 years, Seres Therapeutics' Total Liabilities (Quarterly) stood at $223.4 million in 2021, then spiked by 51.33% to $338.0 million in 2022, then rose by 19.37% to $403.5 million in 2023, then tumbled by 68.76% to $126.0 million in 2024, then slumped by 35.55% to $99.8 million in 2025.
- Its last three reported values are $99.8 million in Q3 2025, $110.8 million for Q2 2025, and $113.7 million during Q1 2025.